Skip to main content
Download PDF

Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

Trials volume 25, Article number: 297 (2024) Cite this article

The Original Article was published on 16 January 2024

Correction: Trials 25, 58 (2024)

https://0-doi-org.brum.beds.ac.uk/10.1186/s13063-023-07834-8


Following publication of the original article [1], we have been notified that a correction is needed on page 3, paragraph 2 as shown below:

Incorrect statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of both octreotide LAR and lanreotide ATG requires medical assistance.”

Correct statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of octreotide LAR requires medical assistance. For patients who receive a stable dose of lanreotide ATG, the product can be administered either by the patient or by a trained person (Reference Somatuline Autogel 60 mg, solution for injection in a prefilled syringe—Summary of Product Characteristics (SmPC)—(emc) (medicines.org.uk)).”

The original article has been corrected.

Reference

  1. Singh S, et al. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024;25:58. https://0-doi-org.brum.beds.ac.uk/10.1186/s13063-023-07834-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sunnybrook Health Sciences Center, Toronto, Canada

    Simron Singh

  2. Endocrinology, Department of Internal Medicine & Medical Specialties, University of Genova, Endocrinology Clinic IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Diego Ferone

  3. Vall d’Hebron University Hospital, Barcelona, Spain

    Jaume Capdevila

  4. Dana-Farber Cancer Institute, Boston, MA, USA

    Jennifer Ang Chan

  5. Erasmus MC & Erasmus MC Cancer Institute, Rotterdam, The Netherlands

    Wouter W. de Herder

  6. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Daniel Halperin

  7. Northern California CarciNET Community, Oakland, CA, USA

    Josh Mailman

  8. Camurus AB, Lund, Sweden

    Lisa Hellström, Hanna Liedman, Agneta Svedberg & Fredrik Tiberg

Authors
  1. Simron Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego Ferone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaume Capdevila
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer Ang Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wouter W. de Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Josh Mailman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lisa Hellström
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hanna Liedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Agneta Svedberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Fredrik Tiberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fredrik Tiberg.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S., Ferone, D., Capdevila, J. et al. Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials 25, 297 (2024). https://0-doi-org.brum.beds.ac.uk/10.1186/s13063-024-08146-1

Download citation

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13063-024-08146-1

Trials

ISSN: 1745-6215